Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals
The purpose of this study is to determine if adult survivors of childhood Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLife (St. Jude Life) protocol are at increased risk for postural control deficits compared to individuals with no cancer history. All participants will be assessed for their ability to maintain an upright posture, walk at their usual speed, and to tandem walk, all while engaged in a cognitive task.
Primary Objective
To compare changes in postural control in ALL survivors to changes in postural control in healthy controls, matched on age- and sex- in simple versus complex standing and walking activities (complex: standing or walking with added cognitive load).
Secondary Objective
To identify demographic and performance related risk factors for decreased postural control during complex standing or walking activities in survivors and controls and to evaluate associations between treatment and the changes in postural control during complex activities among survivors.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Cognitive performance (attention and working memory) will be evaluated using the auditory N-Back test. The 0-back condition and the 2-back condition will be used. After cognitive assessment, participants will perform 3 different postural control tasks (standing balance, regular gait, and tandem gait) in a random order. Postural tasks for each participant will be determined by using random allocation envelopes.
Computerized dynamic posturography will be used to evaluate standing balance with no added cognitive load. Standing balance assessment will be repeated two more times, once with participants engaged in performing the auditory 0-back task, and then with simultaneously performing the auditory 2-back task. Regular gait at participants' preferred speed will be examined using 6 light-weight wearable inertial sensors. The regular walking assessment will be repeated with simultaneous performance of the 0-back task and then with simultaneous engagement in the 2-back task. We have also included a tandem gait (placing one foot directly in front of the other) in order to make the postural task more challenging. The wearable inertial sensors will be used to record participants' gait characteristics while tandem walking. The tandem walk assessment will be repeated once with the participant simultaneously perform the 0-back task and then with the 2-back task. The estimated required time to perform all of the assessments and with inclusion of 3 rest intervals is 2 hours.
In addition, data from the overall SJLIFE assessment will be used in analysis.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38105
- St. Jude Children's Research Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria - Cases:
- Diagnosis of childhood ALL
- At least 5 years post ALL diagnosis
- No history of secondary malignancies after an ALL diagnosis
- Enrollment on the SJLIFE protocol
- Ages 18.00 to 39.99
- Ability to stand and walk for 20 seconds or more
- Ability to answer the eligibility questions
- Ability to provide informed consent
Inclusion Criteria - Controls:
- No history of childhood or adult onset cancer
- Enrollment on the SJLIFE protocol
- Ages 18.00 to 39.99
- Ability to stand and walk for 20 seconds or more
- Ability to answer the eligibility questions
- Ability to provide informed consent
Inclusion of Women and Minorities:
• Male and females of all races and ethnic groups are eligible
Exclusion Criteria:
- Currently receiving treatment for cancer
- Weight ≥ 300 lb (the balance system has a weight limit)
- Does not speak English
- Self-reports of hearing issues
- Pregnant females
- Inability or unwillingness of research participant to give written informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
ALL Survivors
Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
|
|
Control Group
Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Regular gait speed
Délai: Up to 1 hour
|
Regular gait will be evaluated in three different testing conditions: regular gait assessment while participants are engaged in performing a challenging cognitive task (2-back), regular gait assessment while participants are engaged in performing an easy cognitive task (0-bak) and regular gait assessment with no additional cognitive load (baseline).
In each condition, the difference in gait speed of each survivor and his/her matched control will be obtained.
Then the obtained differences at regular gait assessment with no additional cognitive load (baseline) and regular gait while performing the challenging cognitive task (2-bck) will be compared using a paired t-test.
|
Up to 1 hour
|
|
Composite score from standing balance test
Délai: Up to 1 hour
|
Standing balance ability will be examined in three different testing conditions: standing balance while participants are engaged in performing a challenging cognitive task (2-back), standing balance while participants are engaged in performing an easy cognitive task (0-back), and standing balance assessment with no additional cognitive load.
In each condition, the difference in composite score of each survivor and his/her matched control will be obtained.
Then the obtained differences at standing balance assessment with no additional cognitive load (baseline) and standing balance assessment while performing the challenging cognitive task (2-back) will be compared using a paired t-test.
|
Up to 1 hour
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Kristen K Ness, PhD, St. Jude Children's Reearch Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PCALL
- NCI-2018-01471 (Identificateur de registre: NCI Clinical Trial Registration Program)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Leucémie aiguë lymphoblastique
-
Shenzhen Second People's HospitalRecrutementLeucémie | Myéloïde | Chronique | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | PositifChine